Semaglutide tablets for weight loss: what the clinical evidence actually shows

What the MHRA approval and OASIS 4 trial results tell us

The approval of semaglutide weight loss tablets in June 2026 was built on data from the OASIS 4 phase 3 trial: 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, followed over 64 weeks alongside lifestyle changes. The headline figure is a 13.6% average reduction in body weight versus 2.4% on placebo. That average matters: it reflects the full trial population, including people who found the dose escalation difficult or who missed doses. Among participants who stayed fully adherent to the treatment schedule, average weight loss reached approximately 16.6%, a meaningful distinction worth understanding before you set expectations.

Gastrointestinal effects were the most commonly reported side effects, occurring in 74% of those on oral semaglutide versus around 42% on placebo. Most were mild to moderate and tended to settle as the body adjusted. This GI profile is consistent with injectable semaglutide and with GLP-1 medicines generally, as the NHS semaglutide medicines page outlines. Nausea was most noticeable in the early weeks of each dose step, which is part of why the titration moves slowly.

For context on whether oral semaglutide is likely to be a good fit for your situation, our page on whether semaglutide tablets are a good option for weight loss works through the clinical factors in more detail.

How the tablet reaches the bloodstream, and why the morning routine matters

Semaglutide is a large molecule that would ordinarily be broken down in the gut before it could be absorbed. The Wegovy tablet pairs semaglutide with SNAC, an absorption enhancer that briefly raises the local pH in the stomach lining, allowing semaglutide to cross into the bloodstream. The catch is that this mechanism is sensitive to food, liquid and other medicines.

The tablet must be taken first thing in the morning on an empty stomach, swallowed whole with no more than roughly 120ml of plain water. You then wait at least 30 minutes before eating, drinking anything else (including coffee) or taking other oral medicines. Before the kettle has finished boiling is a useful benchmark some people find easy to remember. No fasting beyond that window is needed.

The practical upshot is that oral semaglutide for weight loss fits neatly into a morning routine once the habit is established, and unlike injectable options it requires no refrigeration. The full instructions, including exactly what to do if a dose is missed, are set out in the Patient Information Leaflet; your prescriber is the right person to talk through any adjustments.

The full Wegovy tablet overview on our Wegovy pill page covers storage, the titration timeline, and how the tablet compares to the weekly injection format.

Who the licence covers and what the titration schedule looks like

The MHRA licence applies to adults with a BMI of 30 or above, or a BMI between 27 and 29.9 alongside at least one weight-related condition, for example, high blood pressure, high cholesterol, type 2 diabetes, obstructive sleep apnoea or osteoarthritis. Lower thresholds apply for some ethnic backgrounds under UK guidance. Treatment is used alongside a reduced-calorie diet and increased physical activity, not as a standalone measure.

Treatment starts at 1.5mg daily. The prescriber advances the dose through 4mg and 9mg to the 25mg maintenance dose, with a minimum of one month at each level. Rushing that escalation is not an option; the slow ramp exists to reduce GI side effects and give the body time to adapt. For anyone already established on the 2.4mg weekly injection, the clinical guidance notes a possible direct transition to the 25mg tablet, but that is a prescriber's decision based on your specific history.

A question our prescribers hear fairly often is whether the tablet is covered by the NHS. At the time of writing, Wegovy tablets are not available on the NHS; a NICE appraisal would need to precede any NHS commissioning. That makes private prescription the only current route. Our treatment options page sets out how a private consultation works and what it covers.

Distinguishing Wegovy tablets from Rybelsus, a genuinely important difference

Both Wegovy tablets and Rybelsus contain semaglutide, and both are taken orally. The similarity ends there. Rybelsus is licensed for type 2 diabetes management, at doses of 3mg, 7mg and 14mg, and if you are researching that specific option our page on semaglutide 7mg tablets and their role in weight loss explains what the evidence does and does not support at that dose. Wegovy tablets are licensed for weight management, at doses of 1.5mg, 4mg, 9mg and 25mg. The licensing purposes and dose schedules are completely separate.

This distinction matters because searches for semaglutide tablets can return information about Rybelsus, and it is not unusual for people to arrive at a pharmacy unsure which product applies to their situation. For weight management, the relevant product is the Wegovy tablet. Rybelsus is not licensed, and would not be prescribed, for weight loss in the UK. Our page on Rybelsus and semaglutide tablets for weight loss explains the distinction in full if you have seen the Rybelsus name in your research.

If you want to read about how oral semaglutide compares to the injectable Wegovy format side by side, our Wegovy weight loss tablets page walks through the practical differences. And if you are weighing up semaglutide against other options, including newer formulations such as semaglutide oral liquid, which some people find easier to take than a tablet, the weight loss treatment overview is a good starting point.

Semaglutide tablets for weight loss are a prescription-only medicine. If you think you may be eligible, check your eligibility with our prescribers through a free consultation, a named clinician, not an algorithm, reviews every application the same day.